Veterinary Antifungal Therapeutic Drug Monitoring & Detection

Veterinary Antifungal Therapeutic Drug Monitoring and Detection is utilized in patients with serious fungal infections receiving azole class antifungal drug treatment. It detects the presence and measures the concentration of antifungal drugs in serum or plasma to confirm proper therapeutic levels. Antifungal Therapeutic Drug Monitoring and Detection also helps reduce the risk of developing antifungal drug resistance. MiraVista Diagnostics offers Antifungal Therapeutic Drug Monitoring and Detection for veterinary use.

Antifungal TDM Bioassays for Veterinary Fungal Infections

MiraVista Diagnostics’ antifungal TDM bioassays for veterinary fungal infections are widely used for:

  • Certain azole class antifungal drugs
  • Antifungal drugs with a narrow therapeutic index
  • Antifungal drugs with concentration-dependent clinical efficacy or toxicity
  • Antifungal drugs with an unpredictable dose/level relationship due to variations in bioavailability, metabolism, elimination and drug-drug interactions
Company News

MiraVista Diagnostics Supports Fungal Disease Awareness Week

August 14–18, 2017, is the first Fungal Disease Awareness Week. CDC and partners have organized this week to highlight the importance of recognizing serious fungal diseases early enough in the course of a patient’s illness to provide life-saving treatment. MiraVista…
READ MORE →

MiraVista is Participating in the 2017 Coccidioidomycosis Study Group Symposium

MiraVista Diagnostics is participating in the 2017 Coccidioidomycosis Study Group Symposium on August 11-13 at the Stanford University Medical School. Representatives from the company’s clinical laboratory will be available to discuss MiraVista’s menu of diagnostic tests for serious fungal infections….
READ MORE →

NEW: MVista® Histoplasma Antibody IgG IgM EIA

Improve Diagnosis of Acute Pulmonary Histoplasmosis by Combining Antigen & Antibody Testing Review the technical specifications for the NEW MVista® Histoplasma Antibody IgG IgM EIA>> CLINICAL BACKGROUND Acute pulmonary histoplasmosis (APH) can be severe, especially following heavy exposure and is…
READ MORE →

BULLETIN: CSTE Revised Its Histoplasmosis Position Statement at the 2016 Annual Conference

The Council of State and Territorial Epidemiologists (CSTE) approved the Infectious Disease Committee’s revisions to the histoplasmosis position statement, “Standardized Surveillance Case Definition for Histoplasmosis” at the organization’s annual conference in Anchorage, Alaska on June 19-23, 2016. Review the revised…
READ MORE →

FEATURE: Diagnosing Histoplasmosis by Antigen Detection

FEATURED CASE REPORT FROM THE DESK OF: Lawrence Joseph Wheat, MD Medical Director, Founder & President of MiraVista Diagnostics Here is an important patient case report I’d like to share with colleagues about diagnosing histoplasmosis by antigen detection. I welcome…
READ MORE →

NEW: MVista® Coccidioides Antibody IgG IgM EIA

Improve Coccidioidomycosis Diagnosis with a New, More Sensitive, Anti-Coccidioides Antibody Enzyme Immunoassay CLINICAL BACKGROUND Coccidioidomycosis is endemic to the southwestern United States, northern Mexico and regions of Central and South America. Coccidioidomycosis often presents as community acquired pneumonia (CAP) and…
READ MORE →

LEARN MORE
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo